"id","name","description","rationale","label","uuid:ID","instanceType"
"StudyDesign_1","Study Design 1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","3f4f5f57-731a-4c07-aec2-09ca9a4332c0","StudyDesign"
